Peptidyl-prolyl isomerase F as a prognostic biomarker associated with immune infiltrates and mitophagy in lung adenocarcinoma

被引:0
|
作者
Feng, Zitong [1 ,2 ]
Yuan, Lin [3 ]
Ma, Luyuan [1 ,2 ]
Yu, Wenhao [1 ,2 ]
Kheir, Fayez [4 ]
Kaesmann, Lukas [5 ,6 ,7 ,8 ]
Brueckl, Wolfgang M. [9 ]
Jin, Kai [1 ,2 ]
Wang, Dingxin [1 ,2 ]
Shen, Yi [1 ,2 ]
Li, Rongyang [1 ,2 ]
Tian, Hui [1 ]
机构
[1] Shandong Univ, Dept Thorac Surg, Qilu Hosp, 107 Wen Hua Xi Rd, Jinan 250012, Peoples R China
[2] Shandong Univ, Lab Basic Med Sci, Qilu Hosp, Jinan, Peoples R China
[3] Shandong First Med Univ & Shandong Prov Qianfoshan, Dept Clin Lab Med, Affiliated Hosp 1, Shandong Med & Hlth Key Lab Lab Med, Jinan, Peoples R China
[4] Harvard Med Sch, Massachusetts Gen Hosp, Div Pulm & Crit Care Med, Boston, MA USA
[5] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Radiat Oncol, Munich, Germany
[6] Comprehens Pneumol Ctr Munich CPC M, Munich, Germany
[7] German Ctr Lung Res DZL, Munich, Germany
[8] German Canc Consortium DKTK, Partner Site Munich, Munich, Germany
[9] Paracelsus Med Univ, Gen Hosp Nuernberg, Dept Resp Med Allergol & Sleep Med, Nurnberg, Germany
关键词
Peptidyl-prolyl isomerase F (PPIF); PPIF ); lung adenocarcinoma (LUAD); prognosis; immune; mitophagy; MITOCHONDRIAL PERMEABILITY TRANSITION; CYCLOPHILIN-D; CANCER CELLS; OVEREXPRESSION; OSTEOSARCOMA; INHIBITION; APOPTOSIS; GROWTH; DEATH; PORE;
D O I
10.21037/tlcr-24-344
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Lung adenocarcinoma (LUAD) is among the most prevalent malignancies worldwide, with unfavorable treatment outcomes. Peptidyl-prolyl isomerase F (PPIF) is known to influence the malignancy traits of tumor progression by modulating the bioenergetics and mitochondrial permeability in cancer cells; however, its role in LUAD remains unclear. Our study seeks to investigate the clinical significance, tumor proliferation, and immune regulatory functions of PPIF in LUAD. Methods: The expression of PPIF in LUAD tissues and cells was assessed using bioinformatics analysis, immunohistochemistry (IHC), and Western blotting. Survival curve analysis was conducted to examine the prognostic association between PPIF expression and LUAD. The immunomodulatory role of PPIF in LUAD was assessed through the analysis of PPIF expression and immune cell infiltration. A series of gain- and loss-of-function experiments were conducted on PPIF to investigate its biological functions in LUAD both in vitro and in vivo. The mechanisms underlying PPIF's effects on LUAD were delineated through functional enrichment analysis and Western blotting assays. Results: PPIF exhibited overexpression in LUAD tissues compared to normal controls. Survival curve analysis revealed that patients with LUAD exhibiting higher PPIF expression demonstrated decreased overall survival and a shorter progression-free interval. PPIF was implicated in modulating immune cell infiltration, particularly in regulating the T helper 1-T helper 2 cell balance. Functionally, PPIF was discovered to promote tumor cell proliferation and advance cell-cycle progression. Furthermore, PPIF could impede mitophagy by targeting the FOXO3a/PINK1-Parkin signaling pathway. Conclusions: The findings of this study indicate that the prognosis-related gene PPIF may have a significant role in the regulation of LUAD cell proliferation, tumor-associated immune cell infiltration, and mitophagy, and thus PPIF may be a promising therapeutic target of LUAD.
引用
收藏
页数:20
相关论文
共 50 条
  • [41] Overexpression of peptidyl-prolyl isomerase like-1 is associated with the growth of colon cancer cells (vol 12, pg 70, 2006)
    Obama, K
    Kato, T
    Hasegawa, S
    Satoh, S
    Nakamura, Y
    Furukawa, Y
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (06) : 1947 - 1947
  • [42] Subtractive hybridization analysis of gastric diseases-associated Helicobacter pylori identifies peptidyl-prolyl isomerase as a potential marker for gastric cancer
    Gong, Yue-hua
    Chen, Moye
    Xu, Ying
    Dong, Nannan
    Sang, Zhikun
    Liu, Jun
    Yuan, Yuan
    [J]. FEMS MICROBIOLOGY LETTERS, 2011, 320 (02) : 103 - 109
  • [43] Comprehensive Analysis of NPSR1-AS1 as a Novel Diagnostic and Prognostic Biomarker Involved in Immune Infiltrates in Lung Adenocarcinoma
    Zhang, Hui
    Yuan, Jin
    Xiang, Yuehua
    Liu, Yong
    [J]. JOURNAL OF ONCOLOGY, 2022, 2022
  • [44] Identification of Key Prognostic Biomarker and Its Correlation with Immune Infiltrates in Pancreatic Ductal Adenocarcinoma
    Luan, Hong
    Zhang, Chuang
    Zhang, Tuo
    He, Ye
    Su, Yanna
    Zhou, Liping
    [J]. DISEASE MARKERS, 2020, 2020
  • [45] P4HA1, a Prognostic Biomarker that Correlates With Immune Infiltrates in Lung Adenocarcinoma and Pan-Cancer
    Zhao, Qi
    Liu, Junfeng
    [J]. FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [46] High expression of PTGES3 is an independent predictive poor prognostic biomarker and correlates with immune infiltrates in lung adenocarcinoma
    Gao, Pengxiang
    Zou, Kang
    Xiao, Li
    Zhou, Hongxia
    Xu, Xinping
    Zeng, Zhenguo
    Zhang, Wei
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 110
  • [47] CDK5-REGULATED INTERACTION BETWEEN PEPTIDYL-PROLYL ISOMERASE PIN1 AND MICROTUBLE-ASSOCIATED PROTEIN TAU
    Kimura, T.
    Tsutsumi, K.
    Saito, T.
    Taoka, M.
    Ishiguro, K.
    Isobe, T.
    Uchida, T.
    Hasegawa, M.
    Hisanaga, S.
    [J]. JOURNAL OF NEUROCHEMISTRY, 2011, 118 : 137 - 138
  • [48] CFP is a prognostic biomarker and correlated with immune infiltrates in Gastric Cancer and Lung Cancer
    Cui, Guoliang
    Geng, Le
    Zhu, Li
    Lin, Zhenyan
    Liu, Xuan
    Miao, Zhengyue
    Jiang, Jintao
    Feng, Xiaoke
    Wei, Fei
    [J]. JOURNAL OF CANCER, 2021, 12 (11): : 3378 - 3390
  • [49] MURINE CYCLOPHILIN-S1 - A VARIANT PEPTIDYL-PROLYL ISOMERASE WITH A PUTATIVE SIGNAL SEQUENCE EXPRESSED IN DIFFERENTIATING F9 CELLS
    SCHUMACHER, A
    SCHROTER, H
    MULTHAUP, G
    NORDHEIM, A
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1991, 1129 (01) : 13 - 22
  • [50] Protein Disulfide Isomerase A2 Is Correlated with Immune Infiltrates and Is a Novel Prognostic Biomarker in Glioma Patients
    Zhi-gang Ma
    Ying-xue Liu
    Ning Zou
    Zhe Huang
    Ming Wang
    Tao Li
    Jie Zhou
    Li-gang Chen
    [J]. Current Medical Science, 2023, 43 : 1107 - 1115